Screener
Hemab Therapeutics Holdings, Inc. COAG Income Statement
| Q2 '26 | Q1 '26 | Q2 '25 | ||
|---|---|---|---|---|
| $20.34M+58.0% | $19.46M+38.0% | $12.87M— | ||
| $5.74M+80.4% | $4.15M+68.8% | $3.18M— | ||
| $26.08M+62.4% | $23.61M+42.6% | $16.06M— | ||
| -$26.08M-62.4% | -$23.61M-42.6% | -$16.06M— | ||
| $2.03M-47.4% | $937K-11.9% | $3.85M— | ||
| -$24.05M-97.1% | -$22.68M-46.3% | -$12.21M— | ||
| $97K+2,325% | $12K+106% | $4K— | ||
| -$24.15M-97.8% | -$22.69M-48.2% | -$12.21M— | ||
| -$0.80+93.8% | -$23.98-48.2% | -$12.91— | ||
| -$26M-62.7% | -$23.54M-42.8% | -$15.98M— | ||
| -$26.08M-62.4% | -$23.61M-42.6% | -$16.06M— |
FAQ
- Is Hemab Therapeutics Holdings, Inc. profitable?
- Hemab Therapeutics Holdings, Inc. is not currently profitable: it reported a net loss of $74.4M over the trailing twelve months.
- What is Hemab Therapeutics Holdings, Inc.'s earnings per share?
- Hemab Therapeutics Holdings, Inc.'s diluted EPS over the trailing twelve months is $-53.87.
- Where does Hemab Therapeutics Holdings, Inc.'s income statement data come from?
- Every line is extracted from Hemab Therapeutics Holdings, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.